Latest filing published 05 Mar 2026 for LeonaBio, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Mark James Litton across 2 companies, led by LeonaBio, Inc. and Alder Biopharmaceuticals Inc. Over a trading history stretching from 4 January 2016 to 3 March 2026, the count stands at 14 filings.
No open-market purchase appears, only 2 sales. The totals do not cover 2 filings with an undisclosed amount. Other entries cover 7 share grants and 5 option exercises.
The latest filing, published on 5 March 2026, reports an option exercise in LeonaBio, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations